



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





Rapid AML Therapeutic Panel

Alternative Name

Rapid AML Panel

Methodology

FISH

Molecular

Test Description

The Rapid AML Therapeutic Panel analyzes 13 biomarkers through a combination of bi-directional Sanger sequencing, PCR, and FISH as listed below.

- Sanger sequencing (1 gene): TP53
- PCR/Fragment Analysis (5 genes): FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA
- FISH probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | MLL (11q23) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) | 17p- (TP53 17p13.1, NF1 17q11.2)

Test reports include a summary of all results together.

Clinical Significance

The Rapid AML Therapeutic Panel identifies genetic abnormalities associated with Acute Myeloid Leukemia (AML) that are useful for risk stratification and therapeutic decision making. This panel utilizes a combination of bi-directional Sanger sequencing, PCR and FISH with a fast turnaround time. AML is usually an in-patient hematologic diagnosis and prompt time to treatment assignment can improve patient outcomes significantly.

Specimen Requirements

- **Bone Marrow Aspirate:** 2-3 mL sodium heparin tube. EDTA tube is acceptable.
- **Peripheral Blood:** 3-5 mL sodium heparin tube. EDTA tube is acceptable.
- **Fluids:** Equal parts RPMI to specimen volume.
- **Note:** Please exclude biopsy needles, blades, and other foreign objects from transport tubes. These can compromise specimen viability and yield, and create hazards for employees.

Note: Test in DNA-based, suitable for Freeze & Hold option.

Storage & Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

CPT Code(s)*

Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive™ – Myeloid Disorders, or one of the NeoTYPE® Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.

New York Approved

No

Level of Service

Global

Turnaround Time

4-5 Days for FLT3, IDH1/IDH2, and FISH. 7-10 Days for NPM1, CEBPA, and TP53.

Notes

If ordered alone: 81245x1, 81246 x1, 81310 x1, 81218 x1, 81120 x1, 81121 x1, 81405 x1. FISH: 88374x7

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 050224